EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness of Octocog Alfa ( BAY 81‐8973) to Treat People With Haemophilia A Enrolled in the ATHNdataset , Including Under‐Represented Subgroups

Martin Chandler, Thomas Moulton, Lena Charafi, Jessica Charlet, Michael Recht

European Journal of Haematology · 2025

DOI: 10.1111/ejh.70016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Martin Chandler und 4 weiteren Autor:innen. Beteiligte Einrichtung: American Thrombosis & Hemostasis Network, Rochester, New York, USA. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the real‐world effectiveness of octocog alfa (BAY 81‐8973; Kovaltry) in people with haemophilia A (PwHA), including under‐represented subgroups.

Methods

We retrospectively analysed the American Thrombosis and Hemostasis Network (ATHN) dataset to identify the characteristics, treatment/clinical histories and annualised bleeding rates (ABRs) of PwHA receiving prophylactic or on‐demand octocog alfa. Subgroup analyses included females and those switching to octocog alfa. Data are reported descriptively.

Results

Among 270 PwHA treated with octocog alfa with available bleeding rate data between 1 January 2010 and 31 October 2020, mean (standard deviation) total ABRs were low (0.59 [2.22]) and > 70% of those treated for > 12 months had 0 bleeds. At the second data cutoff (30 April 2022; n = 354), subgroups who switched to octocog alfa from previous treatment had low mean total ABRs after switching, including adolescents (0.83; n = 22), and those previously receiving emicizumab (0.17; n = 17). In females, 10/11 reported 0 bleeds, and of those with joint range of motion data available ( n = 5), 100% had values ≥ 10% below the normal range in ≥ 2 joints.

Conclusions

PwHA treated with octocog alfa in the ATHNdataset, including important subgroups, reported a low number of bleeds; thus, octocog alfa offers an effective therapeutic option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIHumansFemaleMaleAdultRetrospective StudiesAdolescentTreatment OutcomeHemorrhageMiddle AgedChildYoung AdultAgedChild, Preschool

Stichwörter der Autor:innen

Kovaltryadolescentfactor VIIIfactor VIII inhibitorfemaleprophylaxis

Substanzen

Factor VIII

Autor:innen und Institutionen

  • American Thrombosis & Hemostasis Network, Rochester, New York, USA.
  • Bayer U.S. LLC, Whippany, New Jersey, USA.
  • Yale School of Medicine, New Haven, Connecticut, USA.

Förderung

  • Bayer

Zitieren

APA

Chandler, M., Moulton, T., Charafi, L., Charlet, J., & Recht, M. (2025). Effectiveness of Octocog Alfa ( BAY 81‐8973) to Treat People With Haemophilia A Enrolled in the ATHNdataset , Including Under‐Represented Subgroups. European Journal of Haematology. https://doi.org/10.1111/ejh.70016

Vancouver

Chandler M, Moulton T, Charafi L, Charlet J, Recht M. Effectiveness of Octocog Alfa ( BAY 81‐8973) to Treat People With Haemophilia A Enrolled in the ATHNdataset , Including Under‐Represented Subgroups. European Journal of Haematology. 2025. doi:10.1111/ejh.70016

BibTeX
@article{Chandler2025,
  author = {Chandler, Martin and Moulton, Thomas and Charafi, Lena and Charlet, Jessica and Recht, Michael},
  title = {Effectiveness of Octocog Alfa ( BAY 81‐8973) to Treat People With Haemophilia A Enrolled in the ATHNdataset , Including Under‐Represented Subgroups},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.70016}
}
Kostenlos starten →